Residency · Nashville, TN
Sponsored by HCA Healthcare/TriStar Nashville · Director William Maynard
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
The New England journal of medicine · 2021 · 2,130 citations · Jesus Berdeja
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
The New England journal of medicine · 2022 · 1,350 citations · Ian Flinn
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet (London, England) · 2024 · 686 citations · Meredith Mckean
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 1,201 citations · David Spigel
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet (London, England) · 2021 · 1,514 citations · Jesus Berdeja
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
The New England journal of medicine · 2022 · 991 citations · Erika Hamilton
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
The New England journal of medicine · 2023 · 653 citations · Jesus Berdeja
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
The New England journal of medicine · 2022 · 871 citations · Melissa Johnson